January 16th 2021, 7:11pm
January 16, 2021 - Lenvatinib monotherapy was found to be effective in patients with unresectable hepatocellular carcinoma in the United States.
January 16th 2021, 7:00pm
Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.
January 16th 2021, 6:56pm
January 16, 2021 - Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer.
January 16th 2021, 6:47pm
January 16, 2021 - Health-related quality of life during an 18-week period proved to be similar over for patients with esophageal cancer treated with either pembrolizumab or placebo added to chemotherapy.
January 16th 2021, 4:35pm
January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.
January 16th 2021, 3:15pm
OncLive® will be LIVE with OncLive® News Network: On Location at the virtual 2021 ASCO GI. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented in gastrointestinal cancer during the virtual conference.
January 16th 2021, 3:30am
Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.
January 15th 2021, 10:09pm
The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers
January 15th 2021, 9:45pm
January 15, 2021 - As the incidence of colorectal cancer in patients under 50-years-old increases, overall health-related quality of life among younger survivors is poorer, with social and functional well-being suffering more as treatment duration grows longer.
January 15th 2021, 9:33pm
Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer.